Nektar Therapeutics Common Stock, Capital Shares Reserved for Future Issuance
Nektar Therapeutics (NKTR) had Common Stock, Capital Shares Reserved for Future Issuance of 3.30 million shares as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-03-13
- 2025-12-31: Common Stock, Capital Shares Reserved for Future Issuance 3.30M shares.
- 2025-09-30: Common Stock, Capital Shares Reserved for Future Issuance 3.20M shares.
- 2025-06-30: Common Stock, Capital Shares Reserved for Future Issuance 2.83M shares.
- 2024-12-31: Common Stock, Capital Shares Reserved for Future Issuance 4.57M shares; Common Stock, Capital Shares Reserved for Future Issuance as first filed 68.57M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance | Common Stock, Capital Shares Reserved for Future Issuance as first filed |
|---|---|---|
| 2025-12-31 | 3.30M shares 10-K · filed 2026-03-13 | |
| 2025-09-30 | 3.20M shares 10-Q · filed 2025-11-07 | |
| 2025-06-30 | 2.83M shares 10-Q · filed 2025-08-08 | |
| 2024-12-31 | 4.57M shares 10-K · filed 2026-03-13 | 68.57M shares 10-K · filed 2025-03-14 |
| 2023-12-31 | 38.12M shares 10-K · filed 2024-03-05 | |
| 2022-12-31 | 27.40M shares 10-K · filed 2023-02-28 | |
| 2021-12-31 | 26.11M shares 10-K · filed 2022-03-01 | |
| 2011-12-31 | 35.38M shares 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |